Aclaris Therapeutics Inc (ACRS)

Currency in USD
1.575
+0.025(+1.61%)
Real-time Data·
ACRS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
1.5001.859
52 wk Range
1.0505.170
Key Statistics
Prev. Close
1.55
Open
1.61
Day's Range
1.5-1.859
52 wk Range
1.05-5.17
Volume
5.53M
Average Volume (3m)
894.23K
1-Year Change
16.54%
Book Value / Share
1.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACRS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.857
Upside
+398.87%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Aclaris Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Aclaris Therapeutics Inc Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Compare ACRS to Peers and Sector

Metrics to compare
ACRS
Peers
Sector
Relationship
P/E Ratio
−1.3x−2.3x−0.5x
PEG Ratio
0.040.000.00
Price/Book
1.2x2.4x2.6x
Price / LTM Sales
9.6x1.9x3.2x
Upside (Analyst Target)
341.6%116.1%42.0%
Fair Value Upside
Unlock17.1%6.6%Unlock

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.857
(+398.87% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.12 / -0.14
Revenue / Forecast
1.46M / 4.09M
EPS Revisions
Last 90 days

ACRS Income Statement

People Also Watch

1.915
ONDS
+5.22%
26.10
CNC
+2.21%
192.84
IQV
-0.88%
29.74
YOU
+0.34%

FAQ

What Stock Exchange Does Aclaris Therapeutics Inc Trade On?

Aclaris Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Aclaris Therapeutics Inc?

The stock symbol for Aclaris Therapeutics Inc is "ACRS."

What Is the Aclaris Therapeutics Inc Market Cap?

As of today, Aclaris Therapeutics Inc market cap is 170.54M.

What Is Aclaris Therapeutics Inc's Earnings Per Share (TTM)?

The Aclaris Therapeutics Inc EPS (TTM) is -1.44.

When Is the Next Aclaris Therapeutics Inc Earnings Date?

Aclaris Therapeutics Inc will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is ACRS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Aclaris Therapeutics Inc Stock Split?

Aclaris Therapeutics Inc has split 1 times.

How Many Employees Does Aclaris Therapeutics Inc Have?

Aclaris Therapeutics Inc has 63 employees.

What is the current trading status of Aclaris Therapeutics Inc (ACRS)?

As of 30 Jul 2025, Aclaris Therapeutics Inc (ACRS) is trading at a price of 1.58, with a previous close of 1.55. The stock has fluctuated within a day range of 1.50 to 1.86, while its 52-week range spans from 1.05 to 5.17.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.